FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2127858065> ?p ?o ?g. }

• W2127858065 abstract "Abstract Background Thromboembolism (TE) and infection are two common complications of central venous line (CVL). Thrombotic CVL-dysfunction is a common, yet less studied, complication of CVL. Two retrospective studies have reported significant association of CVL-dysfunction and TE. Recent studies indicate association of CVL-related small clot with infection. Infection is the most common cause of non-cancer related mortality in children with cancer. We and others have shown reduced overall survival (OS) in children with cancer and CVL-dysfunction compared to those without CVL-dysfunction. Despite these observations, to date there are no prospective studies to evaluate the clinical significance of CVL-dysfunction and it’s impact on the development of TE, infection, or outcome of children with cancer. Study design This is a prospective, analytical cohort study conducted at five tertiary care pediatric oncology centers in Ontario. Children (≤ 18 years of age) with non-central nervous system cancers and CVL will be eligible for the study. Primary outcome measure is symptomatic TE and secondary outcomes are infection, recurrence of cancer and death due to any cause. Data will be analyzed using regression analyses. Discussion The overall objective is to delineate the relationship between CVL-dysfunction, infection and TE. The primary aim is to evaluate the role of CVL-dysfunction as a predictor of symptomatic TE in children with cancer. We hypothesize that children with CVL-dysfunction have activation of the coagulation system resulting in an increased risk of symptomatic TE. The secondary aims are to study the impact of CVL-dysfunction on the rate of infection and the survival [OS and event free survival (EFS)] of children with cancer. We postulate that patients with CVL-dysfunction have an occult CVL-related clot which acts as a microbial focus with resultant increased risk of infection. Further, CVL-dysfunction by itself or in combination with associated complications may cause therapy delays resulting in adverse outcome. This study will help to identify children at high risk for TE and infection. Based on the study results, we will design randomized controlled trials of prophylactic anticoagulant therapy to reduce the incidence of TE and infection. This in turn will help to improve the outcome in children with cancer." @default.
• W2127858065 created "2016-06-24" @default.
• W2127858065 creator A5017105791 @default.
• W2127858065 creator A5025643656 @default.
• W2127858065 creator A5028711269 @default.
• W2127858065 creator A5029801001 @default.
• W2127858065 creator A5036772616 @default.
• W2127858065 creator A5036975463 @default.
• W2127858065 creator A5040095697 @default.
• W2127858065 creator A5046956758 @default.
• W2127858065 creator A5048306141 @default.
• W2127858065 creator A5051910619 @default.
• W2127858065 creator A5066197445 @default.
• W2127858065 creator A5070607078 @default.
• W2127858065 creator A5081545212 @default.
• W2127858065 date "2012-07-26" @default.
• W2127858065 modified "2023-09-27" @default.
• W2127858065 title "Do children with central venous line (CVL) dysfunction have increased risk of symptomatic thromboembolism compared to those without CVL-dysfunction, while on cancer therapy?" @default.
• W2127858065 cites W119770098 @default.
• W2127858065 cites W1770147359 @default.
• W2127858065 cites W1852065298 @default.
• W2127858065 cites W1910747023 @default.
• W2127858065 cites W1965674493 @default.
• W2127858065 cites W1966988081 @default.
• W2127858065 cites W1967696348 @default.
• W2127858065 cites W1973369259 @default.
• W2127858065 cites W1976249987 @default.
• W2127858065 cites W1978645977 @default.
• W2127858065 cites W1997936886 @default.
• W2127858065 cites W1999920194 @default.
• W2127858065 cites W2003023242 @default.
• W2127858065 cites W2005179828 @default.
• W2127858065 cites W2034576951 @default.
• W2127858065 cites W2037668591 @default.
• W2127858065 cites W2045816462 @default.
• W2127858065 cites W2045967484 @default.
• W2127858065 cites W2053460265 @default.
• W2127858065 cites W2054791306 @default.
• W2127858065 cites W2055397411 @default.
• W2127858065 cites W2067265726 @default.
• W2127858065 cites W2087661939 @default.
• W2127858065 cites W2096911353 @default.
• W2127858065 cites W2097682287 @default.
• W2127858065 cites W2104944704 @default.
• W2127858065 cites W2107419838 @default.
• W2127858065 cites W2109612088 @default.
• W2127858065 cites W2111631254 @default.
• W2127858065 cites W2112145906 @default.
• W2127858065 cites W2112453866 @default.
• W2127858065 cites W2113013505 @default.
• W2127858065 cites W2117345900 @default.
• W2127858065 cites W2120092553 @default.
• W2127858065 cites W2126672009 @default.
• W2127858065 cites W2127153931 @default.
• W2127858065 cites W2130646692 @default.
• W2127858065 cites W2134165426 @default.
• W2127858065 cites W2134820450 @default.
• W2127858065 cites W2135517368 @default.
• W2127858065 cites W2139936875 @default.
• W2127858065 cites W2140976948 @default.
• W2127858065 cites W2143907400 @default.
• W2127858065 cites W2147865643 @default.
• W2127858065 cites W2161375627 @default.
• W2127858065 cites W2162051878 @default.
• W2127858065 cites W2165786903 @default.
• W2127858065 cites W3031602500 @default.
• W2127858065 cites W4366305787 @default.
• W2127858065 cites W67371193 @default.
• W2127858065 doi "https://doi.org/10.1186/1471-2407-12-314" @default.
• W2127858065 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3502590" @default.
• W2127858065 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22835078" @default.
• W2127858065 hasPublicationYear "2012" @default.
• W2127858065 type Work @default.
• W2127858065 sameAs 2127858065 @default.
• W2127858065 citedByCount "7" @default.
• W2127858065 countsByYear W21278580652013 @default.
• W2127858065 countsByYear W21278580652014 @default.
• W2127858065 countsByYear W21278580652015 @default.
• W2127858065 countsByYear W21278580652017 @default.
• W2127858065 countsByYear W21278580652018 @default.
• W2127858065 crossrefType "journal-article" @default.
• W2127858065 hasAuthorship W2127858065A5017105791 @default.
• W2127858065 hasAuthorship W2127858065A5025643656 @default.
• W2127858065 hasAuthorship W2127858065A5028711269 @default.
• W2127858065 hasAuthorship W2127858065A5029801001 @default.
• W2127858065 hasAuthorship W2127858065A5036772616 @default.
• W2127858065 hasAuthorship W2127858065A5036975463 @default.
• W2127858065 hasAuthorship W2127858065A5040095697 @default.
• W2127858065 hasAuthorship W2127858065A5046956758 @default.
• W2127858065 hasAuthorship W2127858065A5048306141 @default.
• W2127858065 hasAuthorship W2127858065A5051910619 @default.
• W2127858065 hasAuthorship W2127858065A5066197445 @default.
• W2127858065 hasAuthorship W2127858065A5070607078 @default.
• W2127858065 hasAuthorship W2127858065A5081545212 @default.
• W2127858065 hasBestOaLocation W21278580651 @default.
• W2127858065 hasConcept C121608353 @default.
• W2127858065 hasConcept C126322002 @default.
• W2127858065 hasConcept C143998085 @default.
• W2127858065 hasConcept C167135981 @default.
• W2127858065 hasConcept C188816634 @default.

• next